In the Virus-Like Particle Translational Oncology Laboratory, Qizhi Cathy Yao, M.D., Ph.D. is developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both ...
Hosted on MSN1mon
Review highlights current understanding of Nipah virus featuresMore information: Limei Wang et al, Nipah virus: epidemiology, pathogenesis, treatment, and prevention, Frontiers of Medicine (2024). DOI: 10.1007/s11684-024-1078-2 Provided by Higher Education Press ...
11d
Pharmaceutical Technology on MSNEC approves Bavarian Nordic’s chikungunya vaccine marketingThe European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...
The formation of VLP is depicted in Figure 1. Figure 1. The formation of a virus-like particle (VLP). Image Credit: Sino Biological Inc. To enable targeted drug research, Sino Biological has ...
Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline ...
Vaccine research has increasingly focused on virus-like particles (VLPs) due to their unique ability to mimic the structures of viruses without containing ...
The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...
ProBioGen has expanded its protein and viral vector manufacturing capabilities at its Berlin headquarters, reinforcing its ...
COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA ® for active ...
GeoVax Labs (NASDAQ:GOVX – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.79) ...
The virus particle comes apart ... viruses are then released from the cell and can go on to infect other cells. Like other viruses, the dengue virus is a microscopic structure that can only ...
Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. COPENHAGEN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results